In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder

Saved in:
Bibliographic Details
Title: In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder
Language: English
Authors: Gidaya, Nicole B., Lee, Brian K., Burstyn, Igor, Yudell, Michael, Mortensen, Erik L., Newschaffer, Craig J.
Source: Journal of Autism and Developmental Disorders. Oct 2014 44(10):2558-2567.
Availability: Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: service-ny@springer.com; Web site: http://www.springerlink.com
Peer Reviewed: Y
Page Count: 10
Publication Date: 2014
Document Type: Journal Articles
Reports - Research
Descriptors: Correlation, At Risk Persons, Autism, Pervasive Developmental Disorders, Pregnancy, Prenatal Influences, Drug Therapy, Clinical Diagnosis, Physical Health, Socioeconomic Status, Effect Size, Children, Foreign Countries
Geographic Terms: Denmark
DOI: 10.1007/s10803-014-2128-4
ISSN: 0162-3257
Abstract: We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark's health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5% of cases and 0.7% of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child's risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
Abstractor: As Provided
Number of References: 58
Entry Date: 2014
Accession Number: EJ1041082
Database: ERIC
Description
Abstract:We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark's health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5% of cases and 0.7% of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child's risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
ISSN:0162-3257
DOI:10.1007/s10803-014-2128-4